http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021213949-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93e8f3f0e161df3d09d4b9a837a21e23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_216cb51c4fc33597e8bd304b3982f849
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-10034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-10034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-295
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
filingDate 2021-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d355df097134d9b718f1bc7c8b743e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4462fa5fda8120276a0feb8b0ab812c9
publicationDate 2021-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2021213949-A1
titleOfInvention A combination of vaccines to prophylactically treat a pig
abstract The invention pertains to a combination of a first vaccine comprising anon-replicating immunogen of porcine circovirus type 2 (PCV-2) and a non-replicating immunogen of Mycoplasma hyopneumoniae, and a second vaccine comprising a live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating a pig against an infection with PCV-2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated separate injection of the first vaccine and the second vaccine into a tissue of the pig at a first and a second injection site respectively, wherein the first and second injection sites are at most 5 cm apart from each other.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114752541-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114752541-B
priorityDate 2020-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008076915-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8728487-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007028823-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014048955-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006074986-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007094893-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018189290-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226423408
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID28280

Total number of triples: 41.